{"id":768921,"date":"2023-07-11T10:58:59","date_gmt":"2023-07-11T14:58:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-novel-mri-biomarker-data-demonstrating-improvement-in-gray-matter-in-patients-with-alzheimers-disease\/"},"modified":"2023-07-11T10:58:59","modified_gmt":"2023-07-11T14:58:59","slug":"inmune-bio-inc-announces-novel-mri-biomarker-data-demonstrating-improvement-in-gray-matter-in-patients-with-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-novel-mri-biomarker-data-demonstrating-improvement-in-gray-matter-in-patients-with-alzheimers-disease\/","title":{"rendered":"INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer\u2019s Disease"},"content":{"rendered":"
\n

\n Analysis of MRI scans in\u00a0participants\u00a0from\u00a0an open label\u00a0Phase\u00a01b study\u00a0demonstrates\u00a0that CDM\u00ae<\/sup>, a\u00a0novel gray matter biomarker,\u00a0is improved following\u00a0three\u00a0months of\u00a0treatment with\u00a0XPro1595TM<\/sup><\/strong>\n <\/p>\n

\n Boca Raton, Florida, July 11, 2023 (GLOBE NEWSWIRE) — <\/strong>
\n
\n INmune Bio Inc.<\/strong>
\n <\/a>\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage immunology company focused on developing treatments that harness the patient\u2019s innate immune system to fight disease, reveals new findings from data\u00a0to be presented at the annual Alzheimer\u2019s Association International Conference (AAIC) in Amsterdam, Netherlands. AAIC is the largest medical meeting focused on Alzheimer\u2019s Disease (AD).<\/p>\n

\u201cOne of the difficulties in developing drugs for AD is the inability to quantify the disease and measure changes at the tissue or microstructure level. The current approaches to measure brain changes utilize imaging techniques that measure the whole brain,\u201d said RJ Tesi, M.D., INmune Bio\u2019s Chief Executive Officer. \u201cTo observe whole brain changes in AD often takes a year or longer. \u00a0Because whole brain changes are a sum of microstructural changes, we can more quickly assess the potential of a therapy through microstructural measurements such as Cortical Disarray Measurement (CDM\u00ae<\/sup>).\u201d <\/p>\n

Emerging imaging techniques that assess microstructural changes are rapidly advancing. \u00a0INmune Bio is a pioneer in the use of novel microstructural neuroimaging biomarkers to measure pharmacodynamic activity of treatment with XProTM<\/sup>\u00a0in patients with AD. INmune\u00a0previously reported<\/a>\u00a0that treatment using XProTM<\/sup>\u00a0improved microstructural changes in the\u00a0white matter<\/a>\u00a0tracts\u00a0<\/a>that are most affected in<\/a>\u00a0AD patients<\/a>\u00a0in participants from our Phase 1b trial. This new analysis reports similar findings in the gray matter of these same participants. The results demonstrate a dose dependent enhancement in gray matter measures throughout the brain in AD patients treated with XProTM<\/sup>. The changes in microstructural cortical gray matter structure were measured using Cortical Disarray Measurement and one metric in particular demonstrated significance PerpPD+. \u00a0CDM\u00ae<\/sup> is a novel gray matter measure that is more effective than standard whole brain volumetric changes in predicting cognitive decline.\u00a0\u00a0 Notably, the greatest improvement was observed in the gray matter of brain regions where Alzheimer\u2019s disease originates.<\/p>\n

To better understand the utility of\u00a0PerpPD+<\/strong>\u00a0in patients with AD treated with XPro\u2122, associations with other AD biomarkers were assessed. \u00a0Baseline levels of\u00a0PerpPD+<\/strong>\u00a0were highly correlated with baseline levels of cerebral spinal fluid biomarkers of AD pathology (amyloid and tau), inflammation (YKL-40, GFAP and sTREM2), and cognitive status (MMSE scores).\u00a0\u00a0\u201cThese data provide additional evidence that\u00a0XProTM<\/sup>\u00a0may be having a specific impact on the brain regions most impacted by AD at the microstructural level within three months of starting treatment,\u201d said CJ Barnum Ph.D., VP of CNS Drug Development at INmune Bio. \u201cThese findings serve as indicators of early target engagement for\u00a0XProTM<\/sup>\u00a0in AD and add further support for use of noninvasive diffusion MRI in AD trials.\u00a0This new biomarker tool, when added to our existing suite of biomarkers, should improve the speed, and decrease the risk of CNS drug development.\u201d<\/p>\n

\n INmune\u00a0Bio\u00a0Presentations\u00a0Discussed\u00a0at AAIC 2023<\/strong>\n <\/p>\n